CRVS at a glance
Corvus Pharmaceuticals, Inc. (CRVS, SEC CIK 1626971) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as June 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Corvus Pharmaceuticals, Inc. (CRVS) shares worth $401.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Moore David Scott on June 11, 2026 of 21,700 shares at $11.53 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $401.2M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing targeted immune cell protein inhibitors for immune-mediated diseases, inflammatory diseases, and cancers
- New emphasis: Soquelitinib advanced to Phase 3 trial for relapsed peripheral T cell lymphoma (PTCL) and initiated Phase 2 trial for moderate-to-severe atopic dermatitis
- Strategic shift: Expanded focus on immune and inflammatory diseases from oncology, demonstrated by ITK inhibitor’s novel mechanism rebalancing Th1/Th2/Th17/Treg cells
- Quantitative highlight: Phase 1/1b trial enrolled 75 PTCL patients; Phase 1 atopic dermatitis trial enrolled 72 patients across 4 cohorts with up to 72% EASI score reduction
- Noteworthy fact: FDA granted Fast Track and Orphan Drug designations for soquelitinib in relapsed PTCL; first clinical evidence of ITK inhibitor therapy efficacy in both cancer and inflammatory disease pathways
Risk Factors
- Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY
- Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028
- Operational risk manufacturing cost increase $4.8M for soquelitinib in 2025, reflecting supply chain cost pressures
- Competitive risk dependence on clinical success of soquelitinib vs oncology market innovations, no approved products yet
- Financial risk reliance on equity funding with $189.4M raised in January 2026 follow-on offering, ATM offering suspended
Management Discussion & Analysis
- Forward-looking statements included but specifics on management outlook or guidance not given
AI summary of the CRVS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No newly triggered risk factor identified; excerpt contains standard carried-forward risks from the 10-K
- Net loss $31.7 million and accumulated deficit $443.9 million as of June 30, 2026
- Cash, equivalents and marketable securities $215.2 million, funding operations into second quarter 2028
- EU Clinical Trials Regulation fully applies after January 31, 2025, increasing compliance requirements for clinical trials
- Clinical-trial delays or adverse results could postpone approval and commercialization of soquelitinib, ciforadenant and mupadolimab
AI summary of the CRVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results covered for periods ended June 30, 2026
- Financial position as of June 30, 2026 and business update furnished in Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ian T. Clark resigning from Corvus Pharmaceuticals’ board effective July 22, 2026
- Departure follows over nine years of board service
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders elected Richard A. Miller and Linda S. Grais as Class I directors through the 2029 annual meeting
- Director support: Miller 58,275,179 votes; Grais 53,185,380 votes
AI summaries of CRVS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRVS
Don't miss the next CRVS filing
- Alerts as it files. A push when CRVS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRVS, by share count.
- Ask anything. An AI agent that reads every CRVS filing and answers with sources.
CRVS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Thompson Peter A. | A | Jun 11, 2026 | 15,000 | - |
| CLARK IAN T | A | Jun 11, 2026 | 15,000 | - |
| van den Broek Richard | A | Jun 11, 2026 | 15,000 | - |
| Grais Linda | A | Jun 11, 2026 | 15,000 | - |
| Moore David Scott | A | Jun 11, 2026 | 15,000 | - |
| Moore David Scott | Buy | Jun 11, 2026 | 21,700 | $11.53 |
| MILLER RICHARD A MD | Buy | May 18, 2026 | 1,932 | $12.01 |
| MILLER RICHARD A MD | Buy | May 18, 2026 | 5,000 | $12.05 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$23.4M | -$27.5M | -$43.0M |
| Net Income | -$27.0M | -$62.3M | -$15.3M |
| Balance Sheet | |||
| Total Assets | $45.6M | $68.9M | $71.1M |
| Equity | $38.7M | $32.6M | $61.2M |
| ROE | -69.9% | -191.3% | -25.0% |
| Per Share | |||
| EPS | $-0.56 | $-1.02 | $-0.53 |
| Cash Flow | |||
| Operating CF | -$23.9M | -$25.4M | -$32.8M |
| CapEx | $34K | - | $174K |
Source: XBRL data in Corvus Pharmaceuticals, Inc. (CRVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CRVS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $401.2M |
| Q1 2026 | 25 | $348.4M |
| Q4 2025 | 20 | $141.1M |
| Q3 2025 | 19 | $86.1M |
| Q2 2025 | 19 | $43.1M |
| Q1 2025 | 15 | $23.0M |
| Q4 2024 | 11 | $21.6M |
| Q3 2024 | 7 | $7.4M |
- BlackRock+978.4K (+16%)
- State Street Corp+908.1K (+25%)
- T. Rowe Price Group+871.8K (+30%)
- Bank of America Corp+520.8K (+220%)
- Two Sigma Investments+245.3K (+45%)
- Morgan Stanley−1.15M (-46%)
- Citadel Advisors LLC−44.6K (-10%)
- JPMorgan Chase & Co−3.2K (-2%)
- FMR LLC (Fidelity)−1.2K (-34%)
- U.S. Bancorp−937 (-85%)
- D.E. Shaw & Co+133.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 141 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRVS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 20, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 27, 2026 | - | - | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 8-K | Mar 13, 2026 | - | Analysis | - |
| 10-K | Mar 12, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Mar 12, 2026 | - | Analysis | - |
| SC 13G | Jan 30, 2026 | - | - | |
| 4 | Jan 30, 2026 | - | - | |
| 8-K | Jan 23, 2026 | - | - | |
| 8-K | Jan 20, 2026 | - | - | |
| 8-K | Jan 20, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CRVS SEC filings: frequently asked questions
Which institutions hold CRVS stock?
As of June 30, 2026, the largest Corvus Pharmaceuticals, Inc. (CRVS) holders among the 13F filers tracked by SignalX were BlackRock ($106.7 million), State Street Corp ($66.8 million), T. Rowe Price Group ($56.6 million), Vanguard Capital Management LLC ($49.2 million), Goldman Sachs Group ($23.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in CRVS's latest 10-K?
In the 10-K filed March 12, 2026, Corvus Pharmaceuticals, Inc. (CRVS) flagged: Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY. Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028. (AI summary of the Risk Factors section.)
What did CRVS report in its latest 8-K?
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and first-half 2026 financial results covered for periods ended June 30, 2026.
What are the latest CRVS SEC filings?
Corvus Pharmaceuticals, Inc. (CRVS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on June 15, 2026.
What is CRVS's SEC CIK number?
Corvus Pharmaceuticals, Inc. (CRVS)'s SEC Central Index Key (CIK) is 1626971. EDGAR lists every CRVS filing under that number.
Ask anything about CRVS
The research agent reads CRVS's filings, financials, insider trades and 13F holders, then answers with sources.